Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.46 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7124182 | 0.82 | ALDH1A1 (0.44) | HCAR2SOAT1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL7124183 | 0.82 | ALDH1A1 (0.44) | HCAR2SOAT1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL7124178 | 0.82 | ALDH1A1 (0.44) | HCAR2SOAT1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL136953 | 0.82 | HCAR2 (0.43) | HCAR2SOAT1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL10394838 | 0.82 | HCAR2 (0.43) | HCAR2SOAT1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL984688 | 0.82 | SOAT1 (0.41) | HCAR2SOAT1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL13296298 | 0.81 | NPSR1 (0.56) | HCAR2SOAT1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL19438257 | 0.81 | NPSR1 (0.56) | HCAR2SOAT1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL28989422 | 0.79 | HCAR2 (0.41) | HCAR2SOAT1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL6439871 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745458-B2 | Azabicyclo (3, 1, 0) hexan derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20090221618-A1 | AZABICYCLO (3, 1, 0) HEXAN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| EP-1926723-B1 | AZABICYCLO (3,1,0) HEXAN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RCEPTORS | GLAXO GROUP LTD (GB) | 2009-05-13 | — | — | EP | disclosed |
| EP-1926723-A2 | AZABICYCLO (3,1,0) HEXAN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RCEPTORS | GLAXO GROUP LIMITED (GB) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007022934-A2 | AZABICYCLO (3, 1, 0) HEXAN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221618-A1 | AZABICYCLO (3, 1, 0) HEXAN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | HTR5A, CHRNA5, DRD3 | HCAR2 382/4885SOAT1 3813/4885ALDH1A1 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.